

Diffuse Large B-Cell Lymphoma (DLBCL)

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Trial Status

Active, not recruiting

Trial Runs In

23 Countries

Trial Identifier

NCT03274492 2017-002023-21
GO39942

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT03274492 2017-002023-21 GO39942

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>= 18 Years & <= 80 Years

Healthy Volunteers

No